SCA
MRNA icon

Sassicaia Capital Advisers’s Moderna MRNA Stock Holding History

Sassicaia Capital Advisers’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,500
Closed -$603K – 30
2024
Q4 		$603K Buy
+14,500
New +$693K 14.58% 2

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sassicaia Capital Advisers's MRNA Position: Q1 2025 in Review

Sassicaia Capital Advisers sold out of Moderna (MRNA) in Q1 2025, closing a stake of 14,500 shares — an estimated $603K sold.

Sassicaia Capital Advisers first reported a position in MRNA in Q4 2024 and held it in 1 quarter. The position peaked at $603K in Q4 2024. 694 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Sassicaia Capital Advisers reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 14,500 Moderna shares in Q1 2025, an estimated $603K.
  • Sassicaia Capital Advisers first reported a position in Moderna in Q4 2024 and held it in 1 quarter.
  • Sassicaia Capital Advisers's Moderna position peaked at $603K in Q4 2024.
  • 694 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Sassicaia Capital Advisers's 13F filing for Q1 2025, filed 15 May 2025.